Status:
COMPLETED
Feasibility of 123I-IBZM Scintigraphy (a D2 Agonist) in Patients With Pheochromocytoma (PHEO) and/or Paraganglioma (PGL) : Study Pilot
Lead Sponsor:
Assistance Publique Hopitaux De Marseille
Conditions:
Chromaffin-tissue Derived Tumors
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Context. Nuclear imaging plays a central role in management of chromaffin-tissue derived tumors because tumor cells exhibit peptide receptors and proteins involved in metabolism that can be targeted w...
Eligibility Criteria
Inclusion
- Age + 18 years. The women in ages to procreate have to have an effective contraception or a negative pregnancy test (in the absence of effective contraception) Having a radiological and functional imaging (balance sheet(assessment) pré--IBZM) considered adapted and complete for the pathology.
- Having a phéochromocytome or a paragangliome proving a surgical operation in view of the data of the balance sheet(assessment) pré--IBZM.
- With or without allergy in the iodine.
Exclusion
- NEM2A or 2B.
- Malignant Forms which do not recover from an even partial, surgical gesture(movement).
- Pregnant Women or in the course of feeding.
- Women in age to procreate without effective contraception, with positive pregnancy test.
- Renal insufficiency
Key Trial Info
Start Date :
February 1 2009
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 1 2012
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT00875407
Start Date
February 1 2009
End Date
July 1 2012
Last Update
February 25 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Assistance Publique-Hopitaux de Marseille
Marseille, France